Anti-cd40 antibodies and methods of use
AssigneeApexigen, Inc.
InventorsYongke ZHANG, Guo-Liang YU, Weimin ZHU
Life of this patent
Estimating the term…
Abstract
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
Claims11
1-36. (canceled)
An isolated polynucleotide encoding an antibody, or antigen-binding fragment thereof, that binds to CD40, wherein said antibody, or antigen-binding fragment thereof, comprises (i) a heavy chain variable region comprising the VHCDR1, VHCDR2, and VHCDR3 set forth in SEQ ID NOs:3-5;
- and (ii) a light chain variable region comprising the VLCDR1, VLCDR2, and VLCDR3 set forth in SEQ ID NOs:6-8;
- or a variant of said antibody, or antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.
An isolated polynucleotide encoding an antibody heavy chain variable region that binds to CD40, wherein said heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:9.
An isolated polynucleotide encoding an antibody light chain variable region that binds to CD40, wherein said light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO:10.
Dependencies are inferred from the claim text.